E Fund CSI Innovative Drugs ETF

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

159859

516080

588130

510660

159849

520880

512010

520690

China is optimizing the pricing mechanism for newly launched medicines, allowing pharmaceutical companies to set prices based on clinical significance and R&D costs. The new policy supports firms in determining initial prices considering market demand and competition, while ensuring patient benefits are prioritized. It clarifies previous ambiguities in drug pricing and allows for stable prices for a certain period post-launch, reflecting a shift towards a market-led pricing mechanism for innovative drugs.

Yicai

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ICBCCS CSI Brand Name Drug Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks

589720

159286

560900

159622

517380

159835

515120

159316

159858

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

CCB Principal CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

GF CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

On April 15th, with favorable policies and a rebound in market risk appetite, the innovative drug sector became active. The E Fund Hang Seng SCHK Innovative Drug ETF (159316) rose by 3.72%, and the E Fund CSI Innovative Drugs ETF (516080) increased by 2.07%. The General Office of the State Council issued opinions on the formation mechanism of drug prices, proposing 14 measures to support the pricing of high-level innovative drugs, marking a policy shift to a new stage of full lifecycle and classified measures, which is beneficial for the expansion of the commercialization space for innovative drugs. It is recommended to pay attention to the E Fund Hang Seng SCHK Innovative Drug ETF (159316) and the E Fund CSI Innovative Drugs ETF (516080)

腾讯新闻 - 财经

BrightGene

THDB

BUCHANG PHARMA

Junshi Biosciences

JUNSHI BIO

Dizal Pharmaceutical

Sunshine Guojian Pharmaceutical

BIOKIN PHARMACEUTICAL

KELUN PHARMA

3SBIO

BIOKIN

The policy side clearly optimizes the pricing mechanism for innovative drugs, focusing on the window for innovative drug layout in the Hong Kong stock market

800医药

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

Yinhua CNI HK Connect Innovative Drugs ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," establishing a pricing governance logic for drugs centered on clinical value and innovation level. Experts indicate that this policy provides stable expectations and autonomous pricing space for the innovative drug industry, promoting industry profitability. In the first quarter, the total amount of external licensing transactions for innovative drugs exceeded USD 60 billion, and the innovative drug sectors in both the A-share and Hong Kong markets rebounded strongly. Despite the favorable policy, the contradictions between medical insurance payments and hospital usage still need to be resolved

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Ping An CSI HK Equities Medical and Health Integration ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

中证医疗

159102

513700

On April 14th, the General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism of Pharmaceuticals," marking the transformation of the pharmaceutical pricing mechanism and promoting high-quality development in the pharmaceutical industry. The new policy formulates differentiated policies for innovative drugs and generic drugs, supports reasonable pricing for innovative drugs, breaks the restrictions of medical insurance payment standards, and encourages enterprise innovation. The generic drug industry will face reshuffling, strengthening centralized procurement regulations, and preventing the impact of low-price bidding on supply. It is expected that small and medium-sized generic drug companies will accelerate elimination, leading to an increase in industry concentration

Huaan Hang Seng Biotech ETF

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

China Southern CNI HK Connect Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua CSI HK Connect Health Care Composite ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Good news! Drug prices are no longer "one-size-fits-all": Innovative drugs can increase prices reasonably, while generic drugs will face survival of the fittest

On April 10th, the innovative drug sector saw a slight rebound, with the Hang Seng SCHK Innovative Drug Index and the CSI Innovative Drugs Industry Index both rising by 0.5%. Against this backdrop, the E Fund Innovative Drug ETF (159316) recorded a net subscription scale of 17 million shares throughout the day. CMB International pointed out that the biopharmaceutical industry has become an emerging pillar industry, with policy dividends continuing to be released. Breakthroughs in AI pharmaceutical technology and cooperation in the overseas expansion of Chinese innovative drugs are forming a dual resonance, and the industry's fundamentals are expected to accelerate positively

The innovative drug sector shows slight signs of recovery. What innovative drug-related ETFs are under E Fund?

On April 9th, despite the innovative drug sector experiencing fluctuations and weakness, the Hang Seng SCHK Innovative Drug Index fell by 1.1%, and the CSI Innovative Drugs Industry Index dropped by 1.3%. However, the E Fund Hang Seng SCHK Innovative Drug ETF (159316) saw a net subscription of 17 million shares against the trend. Guosen Securities pointed out that the government work report has listed biomedicine as an emerging pillar industry for the first time, which is expected to promote industrial innovation and support the development of biomedicine

The innovative drug sector is experiencing fluctuations and adjustments, while E Fund Hang Seng SCHK Innovative Drug ETF (159316) has seen net subscriptions against the trend

02696

During periods of geopolitical turmoil, the A-share innovative drug sector has performed outstandingly, with an increase in industry prosperity and global pharmaceutical companies increasing their investment in the Chinese market. The total amount of license-out in the Greater China region is expected to reach USD 137.7 billion by 2025, with significant growth in both transaction scale and upfront payments. Recent important cooperation deals, such as those between AstraZeneca and CSPC PHARMA, as well as HENLIUS and Eisai, demonstrate the internationalization trend of Chinese innovative drugs. Despite the unstable external environment, the potential of innovative drugs has not yet been fully reflected in asset prices, and more favorable developments are expected in the future

HENLIUS

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Stock Talk | During Geopolitical Turmoil, Why Can A-Share Innovative Drugs Stand Out? The Industrial Logic Has Changed

E Fund CSI Innovative Drugs ETF(516080.SH)

China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

The policy side clearly optimizes the pricing mechanism for innovative drugs, focusing on the window for innovative drug layout in the Hong Kong stock market

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value